LCTX vs LHX · rev $2.8M vs P/E 34, rev $5.88B
Lineage Cell Therapeutics Inc (LCTX) versus L3Harris Technologies Inc (LHX) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
L3Harris Technologies Inc (LHX) is a aerospace & defense company listed on US.
Latest reported LCTX revenue for 2026-06-30 was $2.8M. Net income was -$3.3M. Revenue was up 62.0% from 2026-03-31 to 2026-06-30. LCTX currently screens at market cap $213.6M.
Latest reported LHX revenue for 2026-07-03 was $5.88B. Net income was $600.0M. Revenue was up 2.4% from 2026-04-03 to 2026-07-03. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
LCTX currently screens at market cap $213.6M. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
Not investment advice. Open the LCTX and LHX stock pages for the full models.
Not investment advice.